星状神经节阻滞治疗椎动脉型颈椎病临床观察

我院采用星状神经节阻滞治疗椎动脉型颈椎病122例，获得满意疗效，现报告如下：     

中西医结合治疗椎动脉型颈椎病临床观察

椎动脉型颈椎病是临床上一种常见疾病，主要临床表现为：头痛，头晕，猝倒，自主神经紊乱症状以及视力下降，神经衰弱，严重者可出现锥体束受累症状和共济失调的表现。该病的发病年龄较其他颈椎病高，多在45岁以上，而且发病率随年龄增长有上升的趋势，现日益受到国内外医学界的重视，椎动脉供血不足与该型颈椎病的关系密切。我科采用中西医结合的方法治疗椎动脉型颈椎病取得了满意的疗效，现报道如下：     

手法治疗椎动脉型颈椎病102例

1998年3月至2003年5月，笔者采用手法治疗椎动脉型颈椎病102例，取得了较满意的疗效，现报告如下。     

椎动脉型颈椎病发病机理的研究进展

椎动脉型颈椎病(CSA)是一种常见的疾病,近年来随着对CSA基础研究的进展,学者们已从解剖学和病理生理学角度对本病的发病机理有了深一步的认识。多数学者认为椎—基底动脉系统缺血是引起颈性眩晕症状的重要原因,而其病因可能是椎动脉的直接受压和梗阻或是椎动脉丛受刺激引起动脉管壁的痉挛,后者越来越受到强调而围绕椎动脉型颈椎病发病机理,有多种学说,现就近二十多年来国内外对CSA发病机理方面作一点总结。     

腹针结合颈椎松动术治疗椎动脉型颈椎病

背景：寻找有效改善椎动脉型颈椎病患椎间关节的活动功能、提高临床疗效的方法，提高患的生活质量是目前椎动脉型颈椎病治疗的研究方向。目的：研究腹针结合颈椎松动术治疗椎动脉型颈椎病的临床疗效。设计：随机对照观察。     

手法正骨配合止眩汤治疗椎动脉型颈椎病

椎动脉型颈椎病是由各种机械性与动力性因素所致椎动脉受刺激和压迫以致血管狭窄折曲而造成的椎基底动脉供血不足为主要症状的症候群。采用颈部正骨推拿法配合自拟止眩汤治疗100例，效果满意。     

曲美他嗪联合阿托伐他汀治疗原发性高血压伴阵发性心房颤动的疗效观察

Objective To study the efficacy of trimctazidine combined with atorvastatin for primary hypertension with paroxysmal auricular fibrillation,and its effects on LAD and CRP. Methods 160 patients of pri-mary hypertension with paroxysmal auricular fibrillation were randomly divided into 4 groups. Forty patients were treated with amiodarone (control group),600 mg/d for the first week,400 mg/d for the second week and 200 mg/d later;40 patients were treated with atorvastatin (20 mg/d,3 times per day) in addition to amiodarone (the atorvasat-in group);40 patients were treated with trimetazidine (20 mg/d,3 times per day) in addition to armiodarone (the trimetazidine group);40 patients were treated with combination of trimetazidine and atorvastatin in addition to amiod-atone (the combination group),and the dose was the same as the above groups. The treatment was started within 24 hours of recovering from paroxysmal auricular fibrillation and lasted for 1 year. Results After 1 year there was 1 pa-the control group,and 62.5% (25/40) for the atorvasatin group,64.1% (25/39) for the trimetazidine group,and 84.6% (33/39) for the combination group. Compared to the control group,the effective rate of the 3 treatment groups were all significantly higher (X2=4.56、5.13、17.55,P<0.05). The effective rate of the combination group was significantly higher than that of the atorvasatin group and the trimetazidine group (X2=4.95、4.30,P<0.05),and there was no significant difference of effective rate between the atorvasatin group and the trimetazidine group(X2= >0.05). After treatment LAD was (40.96+1.81) mm in the control group,(38.65±1.90) mm in the atorvasatin group,(39.15±1.85)mm in the trimetazidine group,and (37.22±1.74) mm in the combination group. LAD of the 3 treatment groups were all significantly different from the control group(F=3.42,P<0.05). LAD of the combina-tion group was significantly smaller than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no significant difference of the LAD between the atorvasatin group and the trimetazidine group(P>0.05). There was no significant difference between the 4 groups on CRP before treatment (F=0.96,P>0.05). After treat-ment CRP was (8.85±1.45) mg/L in the control group,(5.96±1.26) mg/L in the atorvasatin group,(6.81± 1.37) mg/L in the trimetazidine group,and (3.75±1.15) mg/L in the combination group. CRP of the 3 treatment groups were all significantly different from the control group (F=3.63,P<0.05). CRP of the combination group was significantly lower than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no signif-icant difference of CRP between the atorvasatin group and the trimetazidine group (P>0.05). Conclusion The treatment with trmetazidine combined with atorvastatin could prevent recurrence of paroxysmal auricular fibrillation though anti-inflammatory and inhibiting the remodeling of left atrial.